Exploratory study for the usefulness of early introduction of anifrolumab in the first remission induction therapy for systemic lupus erythematosus
Recruiting
- Conditions
- systemic lupus erythematosus
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- Diagnosed with SLE based on either the 2019 EULAR/ACR classification criteria or the 1997 ACR classification criteria
- No history of systemic administration of immunosuppressive or immunomodulatory drugs for SLE and within six months of diagnosis
- SLEDAI-2K score of 4 or higher, indicating active disease
- Age 18 years or older and younger than 80 years at the time of obtaining consent
- Patients who have provided written consent for study participation after receiving a full explanation and understanding
Exclusion Criteria
- Steroid therapy exceeding a prednisolone equivalent dose of 0.6mg/kg/day as initial treatment
- Carriers of hepatitis viruses or have active HBV/HCV infections
- History of HBV/HCV infection (excluding cases with negative nucleic acid quantification tests)
- Severe liver disease (AST or ALT >=100 U/L)
- Severe kidney disease (serum creatinine >=2mg/dL)
- Active tuberculosis infection
- Current or history of malignant tumors (excluding cases with no recurrence for more than 5 years, and cervical cancer treated with only with local therapy that remaining in situ and no metastasis for more than 3 years)
- Suspected active infection
- Pregnant or may be pregnant female
- Lactating female
- Coexisting collagen diseases, excluding Sjogren's syndrome and antiphospholipid antibody syndrome
- Within 30 days after receiving live vaccine administration
- Participation in the study is determined as unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- single assignment
- Primary Outcome Measures
Name Time Method - Percentage of patients achieving LLDAS after 12 weeks of anifrolumab initiation.
- Secondary Outcome Measures
Name Time Method